Crispr Therapeutics Ag (CRSP)

CRISPR Therapeutics AG Stock (CRSP) dropped by 2.16% from $53.16 to $52.01 in the trading on Monday November 13, 2023. The reason why CRSP stock down today is due to the recent lower price target by the analysts.

• On Monday, Morgan Stanley analyst Terence Flynn maintained CRISPR Therapeutics with an Underweight and lowered the price target from $43 to $42.
• Last Tuesday, RBC Capital analyst Luca Issi maintains CRISPR Therapeutics with a Sector Perform and lowered the price target from $55 to $50.
• Needham analyst Gil Blum maintained CRISPR Therapeutics with a Buy and lowered the price target from $88 to $85.

CRISPR Therapeutics AG Stock (CRSP) dropped by 6.57% from $45.39 to 42.41 in the trading on Monday October 2, 2023. The reason why stock CRSP is down is due to upcoming FDA decisions for exa-cel. The company is awaiting FDA decisions on its exa-cel gene therapy for sickle cell disease and beta-thalassemia. These decisions are anticipated in the near future, and a few investors might be selling their CRSP shares before the decisions are made, which cause CRSP stock down.